Drug Profile
Ketamine extended release - Douglas Pharmaceuticals
Alternative Names: R-107 - Douglas Pharmaceuticals; R107Latest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Douglas Pharmaceuticals
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Neuroprotectants; Nootropics; Obesity therapies; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 16 Dec 2021 Positive efficacy and safety data from the phase II BEDROC trial in Major depressive disorder released by Douglas Pharmaceuticals
- 16 Dec 2021 Douglas Pharmaceuticals plans a phase III trial for Major depressive disorder in 2022
- 27 Aug 2021 Douglas Pharmaceuticals completes the phase IIa BEDROC trial for Major depressive disorder (Treatment-resistant) in Australia, New Zealand, Singapore, Taiwan (PO) (ACTRN12618001042235)